Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 2/20 | 0.47 |
| ▸ | DGKA | P23743 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | CES2 | O00748 | 3/20 | 0.43 |
| ▸ | CES1 | P23141 | 3/20 | 0.43 |
| ▸ | TSHR | P16473 | 5/20 | 0.43 |
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.42 |
| ▸ | PPARG | P37231 | 6/20 | 0.42 |
| ▸ | PPARD | Q03181 | 6/20 | 0.42 |
| ▸ | PPARA | Q07869 | 6/20 | 0.42 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | TLR2 | O60603 | 2/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
| ▸ | FABP4 | P15090 | 2/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.42 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.42 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | ESR1 | P03372 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7709682 | 1.00 | FAAH (0.47) | FAAHDGKANPSR1CES2CES1 | |
| SCHEMBL28893578 | 1.00 | FAAH (0.47) | FAAHDGKANPSR1CES2CES1 | |
| SCHEMBL3360702 | 1.00 | FAAH (0.47) | FAAHDGKANPSR1CES2CES1 | |
| SCHEMBL15482811 | 1.00 | FAAH (0.47) | FAAHDGKANPSR1CES2CES1 | |
| SCHEMBL13129941 | 1.00 | FAAH (0.47) | FAAHDGKANPSR1CES2CES1 | |
| SCHEMBL6524315 | 1.00 | FAAH (0.47) | FAAHDGKANPSR1CES2CES1 | |
| SCHEMBL7709678 | 1.00 | FAAH (0.47) | FAAHDGKANPSR1CES2CES1 | |
| SCHEMBL15482689 | 1.00 | FAAH (0.47) | FAAHDGKANPSR1CES2CES1 | |
| SCHEMBL13468257 | 1.00 | FAAH (0.47) | FAAHDGKANPSR1CES2CES1 | |
| SCHEMBL6524316 | 1.00 | FAAH (0.47) | FAAHDGKANPSR1CES2CES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8324378-B2 | Prodrugs and conjugates of prenylation inhibitors | PURDUE RESEARCH FOUNDATION (US) | 2012-12-04 | — | — | US | disclosed |
| US-20100249072-A1 | PRODRUGS AND CONJUGATES OF PRENYLATION INHIBITORS | PURDUE RESEARCH FOUNDATION (US) | 2010-09-30 | — | — | US | disclosed |
| WO-2009029849-A1 | PRODRUGS AND CONJUGATES OF PRENYLATION INHIBITORS | PURDUE RESEARCH FOUNDATION (US) | 2009-03-05 | — | — | WO | disclosed |
| EP-1613585-A4 | COMPOUNDS AND METHODS FOR USE IN TREATING NEOPLASIA AND CANCER BASED UPON INHIBITORS OF ISOPRENYLCYSTEINE METHYLTRANSFERASE | PURDUE RESEARCH FOUNDATION (US) | 2008-07-23 | — | — | EP | disclosed |
| US-20070004803-A1 | Compounds and methods for use in treating neoplasia and cancer based upon inhibitors of isoprenylcysteine methyltransferase | PURDUE RESEARCH FOUNDATION (US) | 2007-01-04 | — | — | US | disclosed |
| US-20070004803-A1 | Compounds and methods for use in treating neoplasia and cancer based upon inhibitors of isoprenylcysteine methyltransferase | PURDUE RESEARCH FOUNDATION (US) | 2007-01-04 | — | — | US | disclosed |
| US-20070004803-A1 | Compounds and methods for use in treating neoplasia and cancer based upon inhibitors of isoprenylcysteine methyltransferase | PURDUE RESEARCH FOUNDATION (US) | 2007-01-04 | — | — | US | disclosed |
| WO-2006099313-A2 | PHOSPHATE CONJUGATES OF PRENYLATION INHIBITORS | PURDUE RESEARCH FOUNDATION (US) | 2006-09-21 | — | — | WO | disclosed |
| EP-1613585-A2 | COMPOUNDS AND METHODS FOR USE IN TREATING NEOPLASIA AND CANCER BASED UPON INHIBITORS OF ISOPRENYLCYSTEINE METHYLTRANSFERASE | PURDUE RESEARCH FOUNDATION (US) | 2006-01-11 | — | — | EP | disclosed |
| WO-2004087064-A2 | COMPOUNDS AND METHODS FOR USE IN TREATING NEOPLASIA AND CANCER BASED UPON INHIBITORS OF ISOPRENYLCYSTEINE METHYLTRANSFERASE | PURDUE RESEARCH FOUNDATION (US) | 2004-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070004803-A1 | Compounds and methods for use in treating neoplasia and cancer based upon inhibitors of isoprenylcysteine methyltransferase | BHMT, BHMT2, GNMT | FAAH 2891/4885DGKA 1417/4885NPSR1 3236/4885 |
| US-20100249072-A1 | PRODRUGS AND CONJUGATES OF PRENYLATION INHIBITORS | FNTA, FNTB, FDPS | FAAH 2352/4885DGKA 795/4885NPSR1 3399/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.